[{"Assets_0_Q1_USD":1573600000.0,"CommonStockSharesConverted_0_Q1_shares":74700000.0,"CommonStockSharesOutstanding_0_Q1_shares":74700000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":7800000.0,"NetIncomeLossConverted_1_Q1_USD":-800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":73000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":73000000.0,"StockholdersEquity_0_Q1_USD":1102200000.0,"StockholdersEquityConverted_0_Q1_USD":1102200000.0,"EarningsPerShareBasic_1_Q1_USD":-0.01,"EarningsPerShareDiluted_1_Q1_USD":-0.01,"RevenuesConverted_1_Q1_USD":202300000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2019.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20181107"}]